BioStem CAO acquires 4,234 shares via RSUs
BioStem Technologies, Inc. (BSEM) reports that Chief Accounting Officer Michael A. Fortunato converted 4,234 restricted stock units into 4,234 shares of common stock on September 15, 2026, at no cash exercise price.
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) reports that Chief Accounting Officer Michael A. Fortunato converted 4,234 restricted stock units into 4,234 shares of common stock on September 15, 2026, at no cash exercise price. After this conversion, he holds 68,664 common shares directly and continues to hold multiple option and restricted stock unit awards. No Rule 10b5-1 trading plan is reported for these transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
4,234 shares exercised/converted
Exercise
9 txns
Insider
FORTUNATO MICHAEL A
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F6, F7 | 4,234 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,234 | $0.00 | $0.00 |
| holding | Options (Right to Buy) F1 | -- | -- | -- |
| holding | Options (Right to Buy) F2 | -- | -- | -- |
| holding | Options (Right to Buy) F3 | -- | -- | -- |
| holding | Options (Right to Buy) F4 | -- | -- | -- |
| holding | Options (Right to Buy) F5 | -- | -- | -- |
| holding | Restricted Stock Units F6, F8 | -- | -- | -- |
| holding | Restricted Stock Units F6, F9 | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 55,549 contracts for 38,608 underlying shares (Direct);
Common Stock — 68,664 shares (Direct);
Options (Right to Buy) — 352,468 contracts (Direct)
Footnotes (9)
- F1. These options are fully vested and exercisable.
- F2. These options vest according to the following schedule: 25% vested on January 4, 2024, the one year anniversary of the grant date, with the remaining options vesting in equal monthly installments over the subsequent three year period.
- F3. These options vest according to the following schedule: 33% vested on May 9, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F4. These options vest according to the following schedule: 33%% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F5. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F6. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F7. These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
- F8. These restricted stock units vest according to the following schedule: 33% vested on May 9, 2026, the one-year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
- F9. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
Common shares acquired from RSU conversion: 4,234 shares
Direct common shares held after transaction: 68,664 shares
Options underlying shares at $1.07: 200,000 shares
+5 more
8 metrics
Common shares acquired from RSU conversion
4,234 shares
Common stock received upon conversion of restricted stock units on September 15, 2026
Direct common shares held after transaction
68,664 shares
Direct ownership of BioStem common stock following the September 15, 2026 transactions
Options underlying shares at $1.07
200,000 shares
Underlying common shares for options with a $1.07 exercise price expiring August 16, 2027
Options underlying shares at $2.99
100,000 shares
Underlying common shares for options with a $2.99 exercise price expiring January 4, 2033
Options underlying shares at $15.11 (May 2035 expiration)
11,582 shares
Underlying common shares for options at $15.11 expiring May 9, 2035
Options underlying shares at $15.11 (October 2035 expiration)
2,340 shares
Underlying common shares for options at $15.11 expiring October 13, 2035
Options underlying shares at $5.50
38,546 shares
Underlying common shares for options with a $5.50 exercise price expiring February 11, 2036
Restricted stock units outstanding (two awards)
6,790 and 31,818 units
Each unit represents a contingent right to receive one share of common stock
Key Terms
Restricted Stock Units, Options (Right to Buy), vesting, contingent right
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Options (Right to Buy) financial
"These options vest according to the following schedule"
vesting financial
"These options vest according to the following schedule"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BSEM’s Chief Accounting Officer report on September 15, 2026?
He converted 4,234 restricted stock units into 4,234 shares of common stock on September 15, 2026, at a stated exercise price of $0.00 per share, increasing his directly held common stock position.
Were Michael A. Fortunato’s BSEM transactions made under a Rule 10b5-1 trading plan?
No. The filing indicates that the Rule 10b5-1 trading plan box is not checked, and there are no footnotes describing a pre-arranged trading plan, so no Rule 10b5-1 plan is reported for these equity award transactions.
What option positions does the BSEM Chief Accounting Officer report holding after the transaction?
He reports multiple option awards to acquire BioStem common stock, including options over 200,000 shares at $1.07 expiring August 16, 2027, and additional grants at $2.99, $15.11, and $5.50 with expirations in 2033, 2035, and 2036.
What restricted stock unit awards in BSEM stock does Michael A. Fortunato still hold?
He reports restricted stock units representing 6,790 underlying shares and a separate award representing 31,818 underlying shares of BioStem common stock. Each restricted stock unit represents a contingent right to receive one share of common stock upon vesting.
How do the reported BSEM options and RSUs for the Chief Accounting Officer vest?
Certain options and restricted stock units vest with an initial portion (for example, 25% or 33%) on the one-year anniversary of the grant date, with the remaining portions vesting in equal monthly or quarterly installments over two to three years, as specified in the footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
